Taher Modarressi, Cardiometabolic specialist, Lipid specialist shared a post on X:
“VESALIUS a star of this lipid session at AHA25. Substantial and deeply clinically meaningful benefit w Repatha in primary prevention. Baseline LDL-C 122. Notable ARRs, and 20% decrease in all-cause mortality! Interesting point of support for more intensive lipid lowering therapy even in patients without events.”
More post featuring AHA25 on OncoDaily.
